质子帮浦抑制剂市场：按类型、适应症、剂型、通路、地区

质子帮浦抑制剂的全球市场规模预计到2024年为38.1亿美元，预计到2031年将达到55亿美元，2024年至2031年的复合年增长率为5.4%。

图 1. 2024 年质子帮浦抑制剂市场占有率(%)，依地区划分

质子帮浦抑制剂 (PPI) 是一组透过减少胃酸产生量来发挥作用的药物。 PPI 通常用于治疗胃酸倒流、溃疡和食道发炎。 PPI 透过抑制胃壁细胞表面质子帮浦酶的作用发挥作用。这种酵素负责运输有助于在胃中产生盐酸的离子。透过抑制这种泵，质子帮浦抑制剂可以减少胃酸的产生并缓解胃酸过多的症状。酸相关疾病盛行率的增加、患有此类疾病的老年人口的增加以及医疗保健支出的增加可能会在不久的将来推动全球质子帮浦抑制剂市场的成长。

市场动态：

消化性溃疡和胃食道逆流（GERD）等酸相关疾病的全球盛行率不断上升，可能会推动全球质子帮浦抑制剂市场的成长。由于饮食和生活方式的改变，胃食道逆流症在世界各地变得非常普遍。据估计，GERD 影响着北美 20% 以上的人口。质子帮浦抑制剂是 GERD 患者的第一线药物。老年人口的增加也将推动市场成长，因为老年人更容易罹患与酸相关的疾病。然而，长期使用 PPI 相关的副作用，如肾损伤、骨折、肺炎和营养吸收受损，可能会阻碍市场成长。新兴国家消化器官系统健康意识的提高和医疗保健成本的上升可能为市场参与企业提供机会。

本研究的主要特点

• 该报告对全球质子帮浦抑制剂市场进行了详细分析，以2023年为基准年估计了预测期内（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还揭示了各个细分市场的潜在商机，并解释了该市场中有吸引力的投资提案的矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
• 它根据公司亮点、产品系列、主要亮点、财务业绩和策略等参数，介绍了全球质子帮浦抑制剂市场的主要企业。
• 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球质子帮浦抑制剂市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 透过用于全球质子帮浦抑制剂市场分析的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行概述
• 一致的机会地图 (COM)

第三章 市场动态、法规与趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 监管场景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球质子帮浦抑制剂市场－冠状病毒（COVID-19）大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球质子帮浦抑制剂市场，按类型，2019-2031（十亿美元）

• 介绍
• 奥美拉唑
• 泮他拉唑
• Rabeprazole
• 地克兰索拉唑
• 兰索拉唑
• 其他的

第六章 2019-2031 年全球质子帮浦抑制剂市场（依指标划分）（十亿美元）

• 介绍
• 溃疡
• 胃食道逆流症
• 其他的

第七章全球质子帮浦抑制剂市场，依通路，2019-2031（十亿美元）

• 介绍
• 锭剂
• 胶囊
• 注射
• 其他的

第八章全球质子帮浦抑制剂市场，按剂型，2019-2031（十亿美元）

• 介绍
• 医院药房
• 零售药房
• 网路药房

第九章全球质子帮浦抑制剂市场，按地区，2019-2031（十亿美元）

• 介绍
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第10章竞争格局

• 公司简介
  • AstraZeneca
  • Pfizer
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Procter &Gamble
  • Johnson &Johnson
  • GlaxoSmithKline plc
  • Bayer AG
  • Eisai Co., Ltd.
  • Merck &Co., Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Allergan, Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Perrigo Company PLC.

第十一章分析师建议

• 升起和降落
• 综合机会图

第十二章参考文献与调查方法

• 参考
• 调查方法

Global proton pump inhibitors market is estimated to be valued at USD 3.81 Bn in 2024 and is expected to reach USD 5.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

Figure 1. Proton Pump Inhibitors Market Share (%), By Region, 2024

Proton pump inhibitors (PPIs) are a group of medicines that work by reducing the amount of acid produced in the stomach. PPIs are commonly used to treat acid reflux, ulcers, and inflammation of the esophagus. These work by blocking the action of the proton pump, an enzyme on the surface of gastric parietal cells. This enzyme is responsible for transportation of ions that aid in the production of hydrochloric acid in the stomach. By inhibiting this pump, PPIs decrease acid production and offer relief from conditions caused by excess stomach acid. Growing prevalence of acid related diseases, increasing aging population suffering from such diseases, rising healthcare expenditure can drive the global proton pump inhibitors market growth in the near future.

Market Dynamics:

Rising prevalence of acid-related diseases such as peptic ulcer disease and gastroesophageal reflux disease (GERD) around the world can drive the global proton pump inhibitors market growth. GERD has become highly common worldwide due to changing dietary patterns and lifestyle changes. According to some estimates, GERD affects over 20% of the population in North America. Proton pump inhibitors are first line treatment for GERD patients. Growing geriatric population can also drive the market growth as older people are more prone to acid-related disorders. However, side effects associated with long-term PPI usage such as kidney problems, bone fractures, pneumonia, and interference with absorption of nutrients can hamper the market growth. Growing awareness regarding digestive health and rising healthcare expenditure in emerging nations can offer opportunities for the market players.

Key Features of the Study:

• This report provides in-depth analysis of the global proton pump inhibitors market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global proton pump inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca, Pfizer, Johnson and Johnson, and Bayer
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global proton pump inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global proton pump inhibitors market

Detailed Segmentation-

• By Type
  • Omeprazole
  • Pantaprazole
  • Rabeprazole
  • Dexlansoprazole
  • lansoprazole
  • Others
• By Disease Indication
  • Ulcers
  • Gastroesophageal Reflux Disease
  • Others
• By Dosage Form
  • Tablet
  • Capsules
  • Injection
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca
  • Pfizer
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Procter & Gamble
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Bayer AG
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Reddy's Laboratories Ltd.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Allergan, Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Perrigo Company PLC

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Proton Pump Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Proton Pump Inhibitors Market, By Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Omeprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Pantaprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Rabeprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Dexlansoprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Lansoprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Proton Pump Inhibitors Market, By Disease Indication, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Ulcers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Gastroesophageal Reflux Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Proton Pump Inhibitors Market, By Dosage Form, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Tablet
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Capsules
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Injection
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Proton Pump Inhibitors Market, By Dosage Form, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Proton Pump Inhibitors Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • AstraZeneca
    • Company Highlights
    • Disease Indication Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Procter & Gamble
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Bayer AG
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Allergan, Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Perrigo Company PLC.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. Reference and Research Methodology

• References
• Research Methodology
• About us and Sales Contact